Nivolumab plus ipilimumab for treatment-naïve metastatic uveal melanoma: An open-label, multicenter, phase II trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402)
Source: MDLinx, January 2021
In this single-arm, phase II trial, researchers sought to evaluate the effectiveness of the combination of nivolumab (nivo) plus ipilimumab (ipi) as a first-line therapy with respect to the 12-month overall survival (OS) in patients with metastatic uveal melanoma (MUM) who are not eligible for liver resection.
In total, 52 patients with a median age of 59 years (range, 26-84 years) were registered.
During four inductions, nivo (1 mg/kg once every 3 weeks) and ipi (3 mg/kg once every 3 weeks) were given, followed by nivo (3 mg/kg once every 2 weeks) until progressive disease, toxicity, or withdrawal.
